BioSpace6d
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
Q1 Earnings Estimate for Beam Therapeutics Issued By Wedbush
Equities research analysts at Wedbush upped their Q1 2025 earnings per share estimates for Beam Therapeutics in a research note issued on Monday, March 10th. Wedbush analyst D. Nierengarten now ...
Dealbreaker on MSN6d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush
Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note ...
Beam Therapeutics: Single-Base Editing Seems To Work
The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.
BioPharma Dive7d
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $80 price target on Beam Therapeutics (BEAM) shares after the company ...